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Abstract
The engineering of drug-encapsulated targeted nanoparticles (NPs) has the potential to
revolutionize drug therapy. A major challenge for the smooth translation of targeted NPs to the
clinic has been developing methods for the prediction and optimization of the NP surface
composition, especially when targeting ligands (TL) of different chemical properties are involved
in the NP self-assembly process. Here we investigated the self-assembly and properties of two
different targeted NPs decorated with two widely used TLs that have different water solubilities,
and developed methods to characterize and optimize NP surface composition. We synthesized two
different biofunctional polymers composed of poly(lactide-co-glycolide)-b-polyethyleneglycol-
RGD (PLGA-PEG-RGD, high water solubility TL) and PLGA-PEG-Folate (low water solubility
TL). Targeted NPs with different ligand densities were prepared by mixing TL-conjugated
polymers with non-conjugated PLGA-PEG at different ratios through nanoprecipitation. The NP
surface composition was quantified and the results revealed two distinct nanoparticle assembly
behaviors: for the case of PLGA-PEG-RGD, nearly all RGD molecules conjugated to the polymer
were found to be on the surface of the NPs. In contrast, only ~20% of the folate from PLGA-PEG-
Folate was present on the NP surface while the rest remained presumably buried in the PLGA NP
core due to hydrophobic interactions of PLGA and folate. Finally, in vitro phagocytosis and cell
targeting of NPs was investigated, from which a window of NP formulations exhibiting minimum
uptake by macrophages and maximum uptake by targeted cells was determined. These results
underscore the impact the ligand chemical properties have on the targeting capabilities of self-
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assembled targeted nanoparticles and provide an engineering strategy for improving their targeting
specificity.
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1. Introduction
Targeted nanoparticles (NPs), which have the capability of encapsulating different
therapeutic agents and preferentially delivering them to specific tissues and cells, hold the
promise of revolutionizing the treatment of many diseases including cancer, cardiovascular
diseases, and immunological disorders [1–4]. With respect to cancer, NPs able to
encapsulate chemotherapeutic drugs and directly deliver them to tumor cells can reduce
systemic cytotoxicity caused by these agents and improve their efficacy [5]. Among the
different classes of NPs, polymeric nanoparticles have gained much attention due to several
attractive properties, including biodegradability and biocompatibility of materials, favorable
synthesis conditions, self-assembly in aqueous solution, and requirement of relatively little
post-processing and purification work [6]. A central challenge, however, has been the
development of methods to reproducibly synthesize targeted NPs with well-characterized
and optimized surface compositions. Although there are examples showing the synthesis of
targeted polymeric NPs with different targeting ligands such as the glycoprotein trasnferrin
[7], HER-2 antibody [8], RGD peptide [9], and folic acid [10], it is common to see
characterization and optimization of the surface ligand density underemphasized. Due to the
delicate balance between the amount of targeting ligand to promote effective targeting and
the protective shield (commonly conferred by poly(ethylene glycol), PEG) to avoid immune
detection [11], methods that enable the prediction and characterization of NP surface
composition and the control of NP surface density become essential for the clinical
translation of these vehicles.
Conventional methods of synthesizing polymeric targeted NPs involve use of amphiphilic
block copolymers that self-assemble into drug-encapsulated NP in aqueous solution,
followed by chemical conjugation of the targeting ligands to the surface of the NP [12].
Post-synthesis NP surface modification often requires the addition of excess reactant to
drive the chemical reaction, and thus makes it difficult to adjust the density of TL on NP
surface in a meaningfully reproducible manner. Furthermore, the post-synthesis conjugation
of TL to drug encapsulated NPs is often done under aqueous condition during which there is
an uncontrolled release of the drug from NPs primarily through diffusion. Consequently, the
post-synthesis particle-processing methods offer limited ability to precisely engineer the NP
surface properties in a robust and reproducible manner, and the targeted NPs produced by
such methods may have significant batch-to-batch variations in their biophysicochemical
properties. Our group recently developed a pre-functionalized biopolymer composed of
hydrophobic poly(lactide–co–glycolide) (PLGA) that makes up the NP core, PEG that forms
a corona-like ‘stealth’ shell, and A10 2-fluoropyrimidine RNA aptamer (Apt), which binds
to the prostate-specific membrane antigen (PSMA) on the surface of prostate cancer (PCa)
cells [13]. This functionalized polymer possessed all required components for a targeted NP
and enabled single step self-assembly of targeted functional particles, simplifying the
optimization and the potential manufacturing of the NPs [14].
Extension of this single-step self-assembly technology to other types of targeting molecules,
such as peptides and small molecules with distinct solubilities and modes of action, is
desired along with methods that enable the characterization and optimization of these
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ligands in vitro before embarking on in vivo studies. Likewise, it is of interest to understand
the effect of some of the chemical properties of targeting ligands on the properties and
performance of self-assembled NPs. Currently, two of the most frequently employed
targeting ligands are RGD peptide, which has high water solubility (>50 mg/mL at neutral
pH), and folic acid, which has a relatively poor water solubility (0.0016 mg/mL at neutral
pH) [15]. RGD is a small peptide that preferentially binds to integrin-ανβ3 receptor, which is
often over-expressed in endothelial cells and tumor neovasculature [16]. There are reports
showing preparation of NPs encapsulating drugs and genes in which the RGD ligand enables
preferential targeting of angiogenic tumor blood vessels, thus producing an anticancer
response [17]. Folic acid is a small molecule that binds to the folate receptor, which is over-
expressed in some cancer cells including breast, lung, kidney, ovary, brain, among others
[18]. Although there are a few examples of single-step preparation of NPs using a polymer
functionalized with either RGD or folic acid [9, 19], previous studies lack investigation of
the effects of varying ligand densities on the NP biophysichochemical properties together
with characterization and optimization of the NP surface composition.
This work presents a comparison of the surface composition and targeting specificity of self-
assembled RGD- and Folate-targeted NPs – two widely used TLs with different solubility
profiles. Two different biofunctional polymers composed of PLGA-PEG-RGD (high water
solubility TL) and PLGA-PEG-Folate (low water solubility TL) were synthesized, and
targeted NPs with different ligand densities were prepared by controlling the ratios of TL-
conjugated polymers with non-conjugated PLGA-PEG lacking the TL in a nanoprecipitation
process (otherwise known as solvent displacement method) [20, 21]. The surface ligand
densities of these NPs were quantified and compared to the theoretical ligand densities
estimated from their initial concentrations. Finally, in vitro binding and uptake of these NPs
against macrophages, HUVEC cells (for NP-RGD), and KB cells (for NP-Folate) was
investigated to determine an optimum formulation window where NPs exhibit minimum
uptake by macrophages and maximum uptake by HUVEC cells or KB cells.
2. Materials and Methods
2.1 Materials
Poly(D,L-lactide–co–glycolide)-co-Poly(ethylene glycol) with terminal methoxy groups
(PLGA27K-mPEG5K) was obtained from Boehringer Ingelheim (Ingelheim am Rhein,
Germany). Poly(D,L-lactide–co–glycolide) (50/50) with terminal carboxylate groups
(PLGA, inherent viscosity 0.67 dL/g, MW ~ 45 kDa) was obtained from Lactel (Pelham,
AL, USA). tBOC-NH-PEG-NH2 (MW 5000) and tBOC-NH-PEG-NHS, (MW 5000) were
purchased from Laysan Bio, Inc (Arab, AL, USA). cRGD-PEG4 peptide was obtained from
Peptides International (Louisville, KY, USA) and Folic Acid from Sigma-Aldrich (St. Louis,
MO, USA). Molecular biology buffers and tissue culture reagents were purchased from
Invitrogen (Carlsbad, CA, USA). KB cell line was obtained from American Type Culture
Collection (Manassas, VA, USA), and HUVEC cell line together with its growth medium
was purchased from Lonza, Inc (Allendale, NJ, USA)
2.2 Methods
2.2.1 Synthesis of PLGA-PEG-RGD—The synthesis of PLGA45K-PEG5K-RGD was
accomplished first by the conjugation of a modified cyclic RGD to PEG followed by the
conjugation of the resultant RGD-PEG to PLGA. First, cRGD-PEG4 (Arg-Gly-Asp-D-Phe-
Lys-PEG4) (8 mg, 8.94 μmol) was dissolved in 400 μL of dimethylformamide (DMF) and
reacted with tBOC-NH-PEG-NHS (22 mg, 4.47 μmol) and N,N-Diisopropylethylamine
(DIEA, 10 μL) for 12 h. The reaction product was dialyzed 24 h in water to remove
unreacted RGD. The resultant tBOC-PEG-RGD was lyophilized and reconstituted in 400 μL
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of trifluoroacetic acid (TFA) to remove the protecting group. After 4 h of reaction, product
was dried under vacuum and dissolved in 200 μL of DMSO. Concurrently, PLGA-COOH
(100 mg, 2.22 μmoL) was reacted with N-hydroxysuccinimide (NHS) in the presence of 1-
Ethyl-3-[3-dimethylaminopropyl] carbodiimide (EDC) in dichloromethane (DCM) for 2 h.
PLGA-NHS was dried under vacuum and dissolved in 300 μL of DMSO. Finally, PEG-
RGD and PLGA-NHS in DMSO were mixed with DIEA, allowed to react for 24 h,
precipitated in ice cold methanol, and dried under vacuum. PLGA-PEG-RGD was
characterized with GPC to confirm the presence of the triblock PLGA-PEG-RGD. To verify
conjugation of PEG to RGD Maldi-TOF was used, and it showed that only PEG-RGD was
present while free RGD was absent (see supporting information).
2.2.2 Synthesis of PLGA-PEG-Folate—The synthesis of PLGA45K-PEG5K-Folate was
accomplished first by the conjugation of an activated Folate-NHS to PEG followed by the
conjugation of the resultant Folate-PEG to PLGA. First, Folic acid (60 mg, 0.14 mmol) was
dissolved in 2mL of DMF and reacted with NHS in the presence of EDC for 12 h. Folate-
NHS was precipitated in a mixture of 30/70 acetone/diethyl ether and dried under vacuum.
Dry Folate-NHS was dissolved in 500 μL of DMSO and reacted with tBOC-NH-PEG-NH2
(92.4 mg, 28 μmol) for 12 h in the presence of DIEA. The reaction product was then
precipitated under cool ether, reconstituted in an aqueous solution of NaOH and dialyzed for
48 h. The resultant tBOC-PEG-Folate was lyophilized and reconstituted in 700 μL of TFA
to remove the protecting group. After 4 h of reaction, the solution was dried under vacuum
and then dissolved in 500 μL of DMSO. Concurrently, PLGA-COOH (420 mg, 9.33 μmoL)
was reacted with NHS under the presence of EDC in DCM for 2 h. PLGA-NHS was dried
under vacuum and dissolved in 500 μL of DMSO. Finally, PEG-folate and PLGA-NHS in
DMSO were mixed and allowed to react for 24 h. The final product was precipitated in ice
cold methanol and dried under vacuum. PLGA-PEG-Folate was characterized with NMR to
verify the conjugation of PLGA to PEG, and GPC to confirm the presence of PLGA-PEG-
Folate. To verify conjugation of PEG to folate Maldi-TOF was used, and it showed that only
PEG-folate was present while free folate was absent. Finally to quantify the amount of
PLGA-PEG-Folate compared to PEG-folate, UV-VIS was used and it was found that 98%
of the final reaction product was PLGA-PEG-Folate and 2% PEG-Folate (see supporting
information).
2.2.3 Synthesis of PLGA-Alexa-488—The synthesis of PLGA45K-Alexa488 was
accomplished by the conjugation of an activated PLGA-COOH with Alexa Fluor-488
Cadaverine through EDC/NHS conjugation. First, 1mg of Alexa-488 was dissolved in 1 mL
of DMF. Concurrently, PLGA-COOH (50 mg, 1.1 μmol) was mixed with EDC and NHS in
500 μL of DMF. Finally, PLGA solution was reacted with Alexa-488 solution for 16 h at
room temperature. The reaction product was precipitated in ice cold methanol and dried
under vacuum.
2.2.4 Synthesis and Characterization of NPs—NPs were prepared by the
nanoprecipitation method [20, 21]. In brief, PLGA-mPEG was mixed with a predefined
amount of PLGA-PEG-Folate or PLGA-PEG-RGD and PLGA-Alexa488 in acetonitrile to a
final polymer concentration of 10 mg/mL. For all experiments the weight percent of PLGA-
Alexa488 in the polymer mixture was fixed to 2.5%. At this concentration, PLGA-Alexa488
did not affect the size and zeta potential of the NPs and was readily detected by FACS. For
each NP formulation, 200 μL of the polymer mixture was added drop-wise to water with
constant stirring, giving a final NP concentration of 1 mg/ml. The NPs were stirred for 2 h,
and the remaining organic solvent was removed by washing the NPs three times using an
Amicon centrifugation filtration membrane. Particle sizing was performed using dynamic
light scattering (DLS) with a Zetasizer Nano ZS instrument (Malvern Instruments Ltd.,
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U.K.). For each measurement, 100 μL or more of the sample was loaded in a disposable
low-volume cuvette. The NP surface zeta potential was measured using the same instrument
used for the size measurements. For each measurement, particles were washed with water
and reconstituted in 1 mL of 1× PBS (0.5 mg/mL). TEM experiments were carried out on a
JEOL 2011 instrument at an acceleration voltage of 200 kV. The TEM sample was prepared
by depositing 10 μL of the NP suspension (1.0 mg/mL) onto a 200-mesh carbon-coated
copper grid. Samples were blotted away after 30 min incubation and grids were negatively
stained for 20 min at room temperature with sterile-filtered 2% (w/v) uranyl acetate aqueous
solution.
2.2.5 Quantification of RGD and Folate on Nanoparticle Surface—Detection and
quantification of RGD on the surface of the NP was accomplished using the Lava Prep
Fluorescence-based Peptide Quantification Kit (Gel Company Inc, San Francisco, CA,
USA). Briefly, NP-RGD were prepared and washed three times with DI water to a final
concentration of 1mg/mL. Then, 100 μL of NP solution was mixed with 100 μL of the assay
working solution and incubated for 60 minutes under dark. Fluorescence of the resulting
solution was measured using a PerkinElmer plate reader VICTOR3 (Waltham, MA, USA)
according to manufacturer’s instructions. Using a calibration curve of free cRGD-PEG4, the
amount of RGD present in solution was determined. Each assay was repeated 3 times (each
with n = 8 samples) and the average value was taken as the representative.
Detection and quantification of folate on the NP surface was accomplished first by
incubating NP-Folate with folate antibodies and then determining the amount of antibody
using the Low Protein BCA Assay (Lamda Biotech Inc, St. Louis, MO, USA). Briefly, NP-
Folate was prepared and washed three times with DI water and re-suspended in PBS to a
final concentration of 1 mg/mL. Then, 5 μL of NP solution was mixed with 95 μL of excess
folate antibody in PBS, and the resultant solution incubated for 2 h with slow shaking. After
2 h, excess antibody was removed by washing the NP solution 3 times using a 300 kDa
cutoff centrifugal filter. The final product was re-suspended in 100 μL of PBS followed by
the addition of 100 μL of BCA working solution. The resultant solution was heated at 60 °C
for 30 minutes and analyzed using a UV spectrophotometer according to the manufacturer’s
instructions. Using a calibration curve of free folate antibody, the amount of folate present in
the NP solution was determined. Each assay was repeated 5 times (each with n = 4 samples)
and the average value was taken as the representative. Low BCA assays were done on free
antibody solutions before and after centrifugal filtration to verify that no antibody remained
left on the filter and that the initial amount was recovered after filtration.
2.2.6 NP Binding and Uptake by RAW264.7, KB and HUVEC cells—RAW 264.7
cells were cultured in DMEM medium with 10% fetal bovine serum, 50 units/mL penicillin
and 50 mg/mL streptomycin. KB cells were cultured in Folate-free RPMI medium with 10%
fetal bovine serum, 50 units/mL penicillin and 50 mg/mL streptomycin. HUVEC cells were
cultured in EGM-2 BulleKit medium. All cells were cultured at 37 °C and 5% CO2. Cells
were seeded at a density of 50,000 cells per well on a 24-well plate. After 24 h, the cell
medium was removed and replaced with NPs dissolved in the same medium at a
concentration of 1 mg/mL. Cells and NPs were incubated for 4 h for the case of RAW 264.7
and HUVEC cells and 6 h for case of KB cells followed by three washes with 1% BSA
solution in PBS to remove excess NPs. RAW264.7 cells were removed from the plate using
a cell scraper and centrifuged, while KB and HUVEC cells were treated with trypsin,
removed from the plate, and centrifuged. The resultant cell pellets were reconstituted in
250uL of PBS and placed on a 96-well plate for FACS analysis. Flow cytometry analysis
was performed on a BD Biosciences LSR II with High-Throughput sampler (HTS) option,
with 10,000 cells were collected for each measurement.
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2.2.7 Microscopy of Cells—For fluorescence microscopy studies, KB or HUVEC cells
were seeded on a four-well chamber slide with 20,000 cells/well and incubated at 37°C and
5% CO2 for 24 h. Next, the cells were incubated in fresh complete medium with NPs. After
incubation, cells were washed three times in PBS and fixed in 4% paraformaldehyde at room
temperature. For imaging, slides were mounted with a coverslip using H-1000 Vectorshield
mounting medium with DAPI. Fluorescence imaging was carried out using a Zeiss
Fluorescence Microscope.
3. Results and Discussions
3.1 Synthesis of PLGA-PEG-RGD and PLGA-PEG-Folate
Figure 1A outlines the synthesis procedure of PLGA-PEG-RGD and PLGA-PEG-Folate
block co-polymers. The underlying principles of the synthesis of these two compounds are
the same: conjugation of an amine group (NH2) with a succinimide group in the presence of
a base such a DIEA. The succinimide end group can be obtained from a carboxyl group
(COOH) in the presence of EDC, such as the conversion of PLGA-COOH to PLGA-NHS.
For the case of PLGA-PEG-RGD, the initial materials were the commercially available
modified cyclic RGD (cRGD-PEG4-NH2) and tBOC-NH-PEG-NHS. For the case of PLGA-
PEG-Folate, it is known that the γ-COOH group of folic acid is more reactive when
derivatized and it allows folic acid to maintain its binding properties with the folate receptor
[22]. Therefore, modification of the γ-COOH group of folic acid to NHS was the preferred
strategy. Once folate-NHS was obtained, it was reacted with commercially available tBOC-
NH-PEG-NH2. The chemistry presented here for the synthesis of PLGA-PEG-RGD and
PLGA-PEG-Folate may allow for the conjugation of many targeting ligands (e.g. peptides,
proteins, aptamers, small molecules, etc..), provided there is an available NH2 or COOH
group to be conjugated to PEG, with the PEG conjugate subsequently conjugated to PLGA.
3.2 Synthesis of RGD- and folate-targeted NPs
RGD and folate-targeted NPs were formulated by dissolving PLGA-PEG-RGD or PLGA-
PEG-Folate copolymers with PLGA-mPEG in acetonitrile followed by precipitation in
water. Ligand density was varied by using different percentages of TL-conjugated polymers
in the total polymer formulation (Figure 1B). In principle, the resulting NPs are composed of
a PLGA hydrophobic core, in which hydrophobic drugs can be encapsulated, and a PEG
hydrophilic corona-like shell decorated with targeting moieties. The single-step synthesis
eliminates conjugation steps after particle preparation and enhances batch-to-batch
reproducibility. Prepared targeted NPs were characterized using DLS to measure size and
surface zeta potential, and TEM to observe NP morphology and confirm size.
For NP-RGD it was observed that as the amount of PLGA-PEG-RGD was increased in the
formulation, the surface zeta potential remained close to neutral, which was expected since
PLGA-mPEG has a charge-neutral methoxy end group and RGD in PLGA-PEG-RGD is
also neutral at a pH of 7.4 [23] (Figure 2A). A similar effect was observed for NP-Folate
(Figure 2B). From DLS measurements, NP-RGD had a constant size of ~50 nm for
formulations with 0%, 7%, and 22% PLGA-PEG-RGD. For formulations with 50%, and
74% of PLGA-PEG-RGD a gradual size increase of the NP was observed to 66 nm and 73
nm, respectively (Figure 2C). For NP-Folate, as the amount of PLGA-PEG-Folate was
increased, size increase of NPs was observed for each formulation: 50 nm at 0%, 60 nm at
7%, 76 nm at 22%, 96 nm at 50% and 122 nm at 74% of PLGA-PEG-Folate (Figure 2D).
Considering that both functionalized polymers PLGA-PEG-RGD and PLGA-PEG-Folate
had the similar molecular weight according to GPC ( Mn = 50,005 Da and 49,551 Da,
respectively) and the PLGA-mPEG of same MW was used for both NP formulations, this
disparity in size for NP-Folate suggests that the effect is due to the differences between
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folate and RGD (i.e. presence of folate affects self-assembly). TEM images of both targeted
NPs at a composition of 7% TL-conjugated polymer showed homogenous populations of
NPs with minimal particle-particle aggregation (Figure 2E for NP-RGD and Figure 2F for
NP-Folate).
3.3 NP-RGD and NP-Folate ligand densities
To investigate the effect of targeting ligand hydrophobicity on the surface composition of
NPs, we determined the percentage of the initial RGD or Folate in the form of PLGA-PEG-
RGD and PLGA-PEG-folate present on the surface of the NP in solution. For the case of
NP-RGD we used the Lava Prep Peptide assay, a fluorescence-based method capable of
detecting lysine, arginine, and histidine on peptides. For NP-Folate we first incubated the
NPs with folate antibodies, followed by a washing step to remove excess antibody. Finally,
we used Low BCA protein assay to determine the amount of antibody (and hence the
corresponding amount of folate) on the NP surface. For the case of NP-RGD, all of the RGD
present in the form of PLGA-PEG-RGD was detected on the NP surface (Figure 3A). For
the cases of 75% and 100% RGD, the average fraction of starting RGD presented on the NP
surface appeared to be 0.93 and 0.89, respectively. We believe that at large percentages of
PLGA-PEG-RGD there might be an overlap of RGD molecules that result on the NP surface
which may limit the detection accuracy of the assay, though for percentages of PLGA-PEG-
RGD below 75% this ligand overlap may not occur. In contrast, for NP-Folate a maximum
of 21% of the folate in the form of PLGA-PEG-Folate was detected on the NP surface for all
formulations (Figure 3B). Although the accuracy of this assay may be compromised at high
concentrations of PLGA-PEG-Folate due to steric hindrance of antibodies on the NP
surface, results were found to be reliable for PLGA-PEG-Folate percentages below 74% at
the given NP sizes, since others have detected ~ 4 times the number of antibodies we found
on NPs of similar size [24].
From these results, we hypothesize that the poor water solubility of folate ligands causes
interactions of folate and PLGA when PLGA-PEG-Folate self-assembles into a NP,
resulting in a significant fraction of folate buried in the core of the NP. Conversely, because
RGD has high water solubility, it interacts minimally with PLGA and has minumum
thermodynamic drive to enter the hydrophobic core of the NP. The hypothesis that a
significant fraction of folate molecules from PLGA-PEG-Folate result in the NP core, may
explain the larger NP size observed for higher fractions of PLGA-PEG-Folate. The low
water solubility of folate may present a lower barrier to polymer and NP aggregation during
self-assembly of the NPs, resulting in larger NPs with cores that are more loosely packed
due to inclusion of PEG-Folate blocks of PLGA-PEG-Folate into the NP core. A similar
increase in size of NPs formed by nanoprecipitation was observed previously when PLGA
was added to PLGA-PEG prior to nanoprecipitation [25].
Knowing the size and size distribution of the targeted NPs and assuming an estimated NP
density of 1.27 mg/mL [26], we calculated the ligand density (number of ligands per μm2 of
NP surface) and the number of ligands per NP. Figures 3C and 3D show the theoretical, or
expected, ligand densities calculated assuming 100% of ligands used in NP formulation are
presented on the particle surface, as well as the experimentally determined amount of
targeting ligands detected on the particle surface. For the case of NP-RGD, as the amount of
PLGA-PEG-RGD was increased, the NP ligand density increased, and the observed ligand
densities correlated well with the theoretical calculations. For NP formulations with 5%,
10%, 16%, 22%, 50%, 76% and 100% of PLGA-PEG-RGD the average number of RGD
molecules on the surface of the NP were calculated to be 45, 97, 144, 230, 1030, 2270, and
3731, respectively (Figure 3E). Similarly, for the case of NP-Folate, as the amount of
PLGA-PEG-Folate was increased, the NP ligand density also increased but the theoretical
ligand densities did not correlate well the experimentally determined values. With 7%, 22%,
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50%, and 74% of PLGA-PEG-Folate in the initial formulations, NPs were expected to have
107, 632, 2707, and 12127 ligands on their surface; however, only 23, 89, 368, and 1874
ligands, respectively, were detected on the surface (Figure 3F). The reduced presence of
folate on the surface of the particle may have potential repercussions on the targeting
capabilities of these NPs, which needs to be accounted for future experimental design. These
results highlight the importance of considering the chemical properties of targeting ligands,
such as solubility, as factors that may affect the single-step self-assembly of targeted NPs.
3.5 Cellular binding and uptake of targeted NPs
To examine the effect of ligand solubility on NP binding and uptake we investigated in vitro
the detection of NPs by macrophages and their targeting capabilities to cell models with
over-expressed ligand receptors was investigated in vitro. Phagocytosis of NPs by
macrophages depends both on the size and the surface characteristics of the particle [27].
For instance, hydrophobic surfaces induce opsonization of NPs, which promotes NP
phagocytosis [27, 28]. Conversely, PEG-functionalized and hydrophilic surfaces reduce NP
uptake by macrophages [29]. We investigated the binding and uptake of RGD- and Folate-
targeted NPs by macrophages as the fraction of RGD or folate biofunctional copolymer was
varied. Flow cytometry was used to measure the association of NPs with macrophages, with
2.5% PLGA-Alexa488 added to the NP formulations as a fluorescent reporter. In the case of
NP-RGD, it was observed that as the amount of PLGA-PEG-RGD was increased, there was
no increase in uptake by macrophages when compared to non-targeted (i.e. fully PEG-
functionalized) NPs, with the exception of NPs composed of 74% PLGA-PEG-RGD, which
showed an almost 3-fold increase in uptake (Figure 4A). Although RGD is not known to be
immunogenic [30], the disruption of the outer layer of the PEG shell at high RGD surface
densities might induce an increase in phagocytosis. In contrast, for the case of NP-Folate, as
the PLGA-PEG-Folate was increased, an augment in binding and uptake by macrophages
was observed. Specifically, for NPs composed of 7%, 22%, 50% and 74% PLGA-PEG-
Folate, a 2.0, 3.8, 4.7, and 8.5-fold increase in phagocytosis was observed, respectively
(Figure 4B). It has been shown that NPs of larger size are more readily taken up by
macrophages [31], and hence the observed increase in macrophage uptake could be due an
increase in NP size. Alternatively, this increase in uptake may be due to the low
hydrophilicity of folate which may induce opsonization of the NP surface. Finally, some
reports have shown that NP-Folate target activated macrophages since they have over-
expressed folate receptors [22, 32].
We determined the targeting capabilities of the nanoparticles with RGD and folate at
different densities. We measured the binding and uptake of NP-RGD by HUVEC cells,
which was taken as a model cell line with integrin-ανβ3 receptor over-expressed on the cell
membrane. Similarly, binding and uptake of NP-Folate was investigated using KB cells,
used as a model cell line with folate receptor over-expressed on the cell membrane. Flow
cytometry was used to measure the association of NPs with HUVEC and KB cells, with
2.5% PLGA-Alexa488 added to the NP formulations as a fluorescent reporter. Increase in
the amount of PLGA-PEG-RGD in the NP formulation (which correlates with a higher
number of RGD molecules per NP) resulted in a corresponding increase in fluorescence
associated with HUVEC cells up to ~200-fold when compared to non-targeted NPs (Figure
4C). The increase in RGD molecules on the NP surface may induce multivalent interactions
with the integrin receptors in HUVEC cells leading to increased NP binding and uptake. On
the other hand, for the case of NP-Folate, when the amount of PLGA-PEG-Folate was
increased from 0% to 7%, to 22%, only marginal increase in uptake by KB cells was
observed (Figure 4D). Only at 50% and 74% of PLGA-PEG-Folate was a substantial
increase in uptake observed, with increase in fluorescence associated with the cells of
approximately 4- and 9-fold, respectively, compared to non-targeted NPs. As mentioned
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before, we hypothesize that during self-assembly of PLGA-PEG-Folate and PLGA-mPEG
into a NP, only ~20% of the folate ends up on the NP surface (Figure 3B) and the rest is
embedded in the NP core due to interactions with PLGA. Thus, the amount of folate on the
surface of the NPs may not be sufficient to significantly increase the uptake by KB cells for
formulations with 7% and 22% of PLGA-PEG-Folate. The NP surface folate concentration
was sufficient to elicit a significant increase in uptake by KB cells only when > 50% PLGA-
PEG-Folate was used in NP formulation.
From these results one can determine optimal NP candidates for future experiments. For the
case of NP-RGD, formulations composed of up to 50% PLGA-PEG-RGD could be used
since they experienced marginal phagocytosis compared to non-targeted NPs and a ~70-fold
increase in fluorescence when exposed to HUVEC cells. In contrast, for NP-Folate only
those formulations with ~50% PLGA-PEG-Folate could be used since below this percentage
only modest targeting effects were observed and above this percentage increased
phagocytosis was observed. Microscopy images presented in figures 4E and 4F show that
non-targeted NPs do not enter, or minimally enter, the cell while targeted NP-RGD and NP-
Folate composed 50% TL-conjugated polymer readily enter HUVEC cells and KB cells,
respectively. NP formulations with narrower ranges of the fraction of TL-conjugated
biopolymer together with other in vitro experiments that investigate complement activation
[33], cell cytotoxicity [34], among other factors [35], could be carried out to narrow the
window of optimal NP candidates for in vivo experiments.
4. Conclusions
We synthesized PLGA-PEG copolymers functionalized with either folic acid (a ligand with
poor water solubility) or RGD peptide (a ligand with high water solublity), for single-step
preparation of targeted polymeric nanoparticles. By mixing PLGA-PEG-RGD or PLGA-
PEG-Folate with PLGA-mPEG at different ratios we were able to prepare NPs with varying
surface ligand densities. The surface of the targeted NPs was characterized, demonstrating
that all of the RGD included in the form of PLGA-PEG-RGD was present on the surface of
the NP-RGD while only ~20% of the folate in the form PLGA-PEG-Folate was found on the
NP-Folate surface. Uptake of targeted NPs by macrophages was investigated showing that
NP-Folate was increasingly taken up as the amount of PLGA-PEG-Folate in the formulation
was increased, while NP-RGD experienced minimum phagocytosis even at 50% PLGA-
PEG-RGD. Finally, we studied the association of NP-RGD with HUVEC cells and NP-
Folate with KB cells showing that as the concentration of PLGA-PEG-RGD in the NP-RGD
formulation was increased a corresponding increase in uptake was observed, while NP-
Folate only showed significant targeting at ~50% PLGA-PEG-Folate. These studies provide
insight into the behavior of targeted NPs prepared in a single-step with TLs of different
solubilites and show an in vitro experimental design for finding NPs with favorable targeting
ligand density.
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Figure 1.
(A) Synthesis of PLGA-PEG-RGD and PLGA-PEG-Folate. (B) Preparation of targeted NPs
with different surface ligand densities by mixing PLGA-mPEG with functionalized PLGA-
PEG-TL.
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Figure 2.
Characterization of targeted NP-RGD and NP-Folate: Zeta Potential (A,B) Size (C, D) and
TEM micrographs (E,F). Error bars represent standard deviation of n = 3 samples.
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Figure 3.
Quantification of targeted NP surface composition. (A) Fraction of initial RGD that resulted
on the NP surface. (B) Fraction of initial folate that resulted on the NP surface. (C)
Estimated ligand Densities and (E) estimated number of ligands per NP of NP-RGD as a
function of the percentage of PLGA-PEG-RGD in formulation. (D) Estimated ligand
Densities and (F) estimated number of ligands per NP of NP-Folate as a function of the
percentage of PLGA-PEG-Folate in formulation. Theoretical (□) and experimental (Δ).
Error bars represent standard deviation in n = 8 samples for NP-RGD and n = 4 samples for
NP-Folate.
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Figure 4.
Cellular binding and uptake of targeted NPs as a function of % of functionalized PLGA-
PEG added in the NP formulation. (A) RGD targeted PLGA-PEG NPs and (B) Folate-
targeted PLGA-PEG NPs. (C) Association of NP-RGD with HUVEC cells. (D) Association
of NP-Folate with KB cells. (E) Representative images of non-targeted and NP-RGD (at
50% of PLGA-PEG-RGD) uptake by HUVEC cells. (F) Representative images of non-
targeted and NP-Folate (at 50% PLGA-PEG-Folate) uptake by KB cells. Error bars
represent standard deviation in n = 3 samples.
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